Adherence and Persistence with Once-Daily Teriparatide in Japan: A Retrospective, Prescription Database, Cohort Study

Table 2

Adherence and persistence with once-daily teriparatide during the 12-month study period.

Variable	All (𝑁=123)	Time frame of treatment^a
		Early; (𝑁=50)	Later; (𝑁=73)
Adherence
MPR^b, mean (SD)	0.702 (0.366)	0.640 (0.398)	0.745 (0.339)
MPR > 0.8, n (%)	75 (61.0)	27 (54.0)	48 (65.8)
Persistence
Estimated TTD^c, days
25th percentile	95	60	161
50th percentile	Censored (≥365)	Censored (≥365)	Censored (≥365)
75th percentile	Censored (≥365)	Censored (≥365)	Censored (≥365)
Actual TTD, n (%)
>0 days	123 (100.0)	50 (100.0)	73 (100.0)
>60 days	99 (80.5)	37 (74.0)	62 (84.9)
>120 days	91 (74.0)	33 (66.0)	58 (79.5)
>180 days	81 (65.9)	29 (58.0)	52 (71.2)
>240 days	80 (65.0)	29 (58.0)	51 (69.9)
>300 days	76 (61.8)	28 (56.0)	48 (65.8)
>360 days	75 (61.0)	28 (56.0)	47 (64.4)
≥365 days (censored)	75 (61.0)	28 (56.0)	47 (64.4)

MPR: medication possession ratio; SD: standard deviation; TTD: time to discontinuation.
aEarly initiators started treatment during months 1–4 of once-daily teriparatide availability, whereas later initiators started treatment during months 5–8 of once-daily teriparatide availability.
bThe sum of the days’ supply of medication dispensed between the start and the end of the study period divided by the total number of days (365) in the study period.
cTime from the start of treatment to the discontinuation of treatment. Discontinuation was defined as a 60-day gap in once-daily teriparatide supply.